[ad_1]

The Cell and Gene Therapy Catapult has partnered with MICA Biosystems to start the journey of bringing their revolutionary regenerative drugs know-how to the MHRA.

London tenth February 2022: The Cell and Gene Therapy Catapult (CGT Catapult), an impartial innovation and know-how organisation specialising within the development of cell and gene therapies, proclaims a collaboration with MICA Biosystems (MICA), a Birmingham primarily based medical know-how firm, to leverage the experience of the CGT Catapult in taking novel applied sciences and ideas by means of to medical trials.

MICA have developed a ground-breaking platform that makes use of patented nanotechnology to regulate a affected person’s stem cells, in situ, to restore or exchange broken or diseased tissue. The first software of MICA’s know-how is in spinal fusion, a kind of spinal restore, with the process solely requiring an out-patient intervention utilizing simply two needles and a take-home bandage.

In the long run, the MICA staff goals to use this pioneering new process to the sector of regenerative drugs and potential purposes for the platform embody; arthritis, tendon restore, osteoporosis, spinal wire restore, and a therapy for neurodegenerative illnesses. In the phrases of MICA’s Managing Director, Dr.Alicia El Haj: “Stem cell remedy will likely be introduced from the fringes to the forefront of therapy choices.”

This collaboration between the CGT Catapult and MICA, which is able to show to be key for MICA as they interact in conversations with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) the place alignment is essential to make sure a clean transition into, and thru, future medical trials.

Dr. Michal Zurawski, Chief Executive Officer at MICA Biosystems remark:

“This collaboration will present a lift to make sure MICA is ready to start medical trials in a well timed method and, most significantly, enable our know-how to achieve sufferers sooner. This new chapter in our growth was made doable by an injection of funding from the UK Government and Innovate UK, recognising MICA as an actual innovator and disruptor within the house of regenerative drugs. With the experience and expertise of the CGT Catapult, we intention to launch our medicines as an accessible therapy choice for tens of millions of sufferers with quite a lot of life-changing illnesses and accidents which at the moment have restricted or no therapy choices.”

Matthew Durdy, Chief Executive Officer at Cell and Gene Therapy Catapult commented:

“Our imaginative and prescient for the CGT Catapult is to assist develop a thriving trade delivering life altering superior therapies to the world. We are wanting ahead to working with MICA as an modern firm and welcome the assist from the Innovate UK EDGE fund that may allow this collaboration to leverage our distinctive experience to assist deliver MICA’s modern know-how options to sufferers.”

About MICA Biosystems

MICA Biosystems is the world’s first, First-in-Class superior remedy firm, which makes use of nanotechnology to create a remote-controlled stem cell platform for regenerative drugs. The firm goals so as to add years to life and life to years throughout all age teams and in quite a lot of therapeutic areas, by unlocking the potential of stem cells whereas utilizing the sufferers’ personal cells, with no prolonged, and expensive, cell tradition course of in any respect. MICA’s know-how brings with it the potential to deliver regenerative drugs to the forefront of drugs globally, with a enterprise funding spherical opening in Q2 2022. For extra data, go to www.MICABIOSYSTEMS.co.uk

About the Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult is an impartial innovation and know-how organisation dedicated to the development of cell and gene therapies with a imaginative and prescient of a thriving trade delivering life altering superior therapies to the world. Its intention is to create highly effective collaborations which overcome challenges to the development of the sector. With over 400 consultants overlaying all facets of superior therapies, it applies its distinctive capabilities and property, collaborates with academia, trade and healthcare suppliers to develop new know-how and innovation. The Cell and Gene Therapy Catapult works with Innovate UK. For extra data, please go to ct.catapult.org.uk or go to http://www.gov.uk/innovate-uk.

[ad_2]

Source link

#MICA #Biosystems #collaborate #Cell #Gene #Therapy #Catapult

By Seth A. Dunbar

Seth Dunbar leads clinical research study operations and quality & compliance. He is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published.